Role of complement C5a in mechanical inflammatory hypernociception: Potential use of C5a receptor antagonists to control inflammatory pain

British Journal of Pharmacology

Volumn 153, Issue 5, 2008, Pages 1043-1053

  Ting, E ^a   Guerrero, A T G ^a   Cunha, T M ^a   Verri Jr , W A ^a   Taylor, S M ^b   Woodruff, T M ^b   Cunha, F Q ^a   Ferreira, S H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

C5a; Complement system; Cytokines; Hyperalgesia; Inflammatory pain; Neutrophils

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTIGEN; ANTIINFLAMMATORY AGENT; CARRAGEENAN; CYTOKINE; DOPAMINE; LIPOPOLYSACCHARIDE; PMX53; PROSTAGLANDIN E2; PROTEIN C5A; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOUSE; NEUTROPHIL; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

EID: 40349096513     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707640     Document Type: Article

References (61)

1. Akama H, Ichikawa Y, Matsushita Y, Shinozawa T, Homma M (1990). Mononuclear cells enhance prostaglandin E2 production of polymorphonuclear leukocytes via tumor necrosis factor alpha. Biochem Biophys Res Commun 168: 857–862.
2. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM (2004). The role of the complement system in ischemia–reperfusion injury. Shock 21: 401–409.
3. Bazargani F (2005). Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms. Swed Dent J Suppl 1–57: i.
4. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206–209.
5. Castellheim A, Pharo A, Fung M, Saugstad OD, Mollnes TE (2005). Complement C5a is a key mediator of meconium‐induced neutrophil activation. Pediatr Res 57: 242–247.
6. Chenoweth DE, Hugli TE (1978). Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 75: 3943–3947.
7. Clark JD, Qiao Y, Li X, Shi X, Angst MS, Yeomans DC (2006). Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression. Anesthesiology 104: 1274–1282.
8. Coutaux A, Adam F, Willer JC, Le Bars D (2005). Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine 72: 359–371.
9. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH (1991). Interleukin‐8 as a mediator of sympathetic pain. Br J Pharmacol 104: 765–767.
10. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH (1992). The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107: 660–664.
11. Cunha JM, Sachs D, Canetti CA, Poole S, Ferreira SH, Cunha FQ (2003). The critical role of leukotriene B4 in antigen‐induced mechanical hyperalgesia in immunised rats. Br J Pharmacol 139: 1135–1145.
12. Cunha TM, Verri Jr WA, Poole S, Parada CA, Cunha FQ, Ferreira SH (2007). Pain facilitation by proinflammatory cytokine actions at peripheral nerve terminals. In: DeLeo J, Sorkin L, Watkins L (eds). Immune and Glial Regulation of Pain. IASP Press: Seattle.
13. Cunha TM, Verri Jr WA, Silva JS, Poole S, Cunha FQ, Ferreira SH (2005). A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA 102: 1755–1760.
14. da Rocha FA, Teixeira MM, Rocha JC, Girao VC, Bezerra MM, Ribeiro Rde A et al. (2004). Blockade of leukotriene B4 prevents articular incapacitation in rat zymosan‐induced arthritis. Eur J Pharmacol 497: 81–86.
15. de Abreu Castro MS, Ferreira SH (1979). Cell migration and hyperalgesia: a paradoxical effect of endotoxin. Adv Inflamm Res 1: 311–316.
16. Fayyazi A, Sandau R, Duong LQ, Gotze O, Radzun HJ, Schweyer S et al. (1999). C5a receptor and interleukin‐6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol 154: 495–501.
17. Ferreira SH, Cunha FQ, Lorenzetti BB, Michelin MA, Perretti M, Flower RJ et al. (1997). Role of lipocortin‐1 in the anti‐hyperalgesic actions of dexamethasone. Br J Pharmacol 121: 883–888.
18. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S (1988). Interleukin‐1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334: 698–700.
19. Ferreira SH, Lorenzetti BB, Correa FM (1978a). Central and peripheral antialgesic action of aspirin‐like drugs. Eur J Pharmacol 53: 39–48.
20. Ferreira SH, Lorenzetti BB, Poole S (1993). Bradykinin initiates cytokine‐mediated inflammatory hyperalgesia. Br J Pharmacol 110: 1227–1231.
21. Ferreira SH, Nakamura M (1979a). II—Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins 18: 191–200.
22. Ferreira SH, Nakamura M (1979b). III—Prostaglandin hyperalgesia: relevance of the peripheral effect for the analgesic action of opioid‐antagonists. Prostaglandins 18: 201–208.
23. Ferreira SH, Nakamura M, de Abreu Castro MS (1978b). The hyperalgesic effects of prostacyclin and prostaglandin E2. Prostaglandins 16: 31–37.
24. Freund J (1956). The mode of action of immunologic adjuvants. Bibl Tuberc 10: 130–148.
25. Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C (1989). Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J Biol Chem 264: 1760–1766.
26. Griffin RS, Costigan M, Brenner GJ, Ma CH, Scholz J, Moss A et al. (2007). Complement induction in spinal cord microglia results in anaphylatoxin C5a‐mediated pain hypersensitivity. J Neurosci 27: 8699–8708.
27. Guerrero AT, Verri Jr WA, Cunha TM, Silva TA, Rocha FA, Ferreira SH et al. (2006). Hypernociception elicited by tibio‐tarsal joint flexion in mice: a novel experimental arthritis model for pharmacological screening. Pharmacol Biochem Behav 84: 244–251.
28. Guerrero AT, Verri Jr WA, Cunha TM, Silva TA, Schivo IR, Dal‐Secco D et al. (2008). Involvement of LTB4 in zymosan‐induced joint nociception in mice: participation of neutrophils and PGE2. J Leukoc Biol 83: 9.
29. Hawlisch H, Wills‐Karp M, Karp CL, Kohl J (2004). The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 41: 123–131.
30. Haynes DR, Harkin DG, Bignold LP, Hutchens MJ, Taylor SM, Fairlie DP (2000). Inhibition of C5a‐induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol 60: 729–733.
31. Hetland G, Pfeifer PH, Hugli TE (1998). Processing of C5a by human polymorphonuclear leukocytes. J Leukoc Biol 63: 456–462.
32. Issekutz TB, Miyasaka M, Issekutz AC (1996). Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J Exp Med 183: 2175–2184.
33. Khasar SG, McCarter G, Levine JD (1999). Epinephrine produces a beta‐adrenergic receptor‐mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 81: 1104–1112.
34. Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M et al. (1998). Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 41: 233–245.
35. Kodani M, Sakata N, Takano Y, Kamiya H, Katsuragi T, Hugli TE et al. (2000). Intratracheal administration of anaphylatoxin C5a potentiates antigen‐induced pulmonary reactions through the prolonged production of cysteinyl‐leukotrienes. Immunopharmacology 49: 263–274.
36. Laudes IJ, Chu JC, Huber‐Lang M, Guo RF, Riedemann NC, Sarma JV et al. (2002). Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 169: 5962–5970.
37. Lavich TR, Siqueira Rde A, Farias‐Filho FA, Cordeiro RS, Rodrigues e Silva PM, Martins MA (2006). Neutrophil infiltration is implicated in the sustained thermal hyperalgesic response evoked by allergen provocation in actively sensitized rats. Pain 125: 180–187.
38. Levine JD, Gooding J, Donatoni P, Borden L, Goetzl EJ (1985). The role of the polymorphonuclear leukocyte in hyperalgesia. J Neurosci 5: 3025–3029.
39. Linton SM, Morgan BP (1999). Complement activation and inhibition in experimental models of arthritis. Mol Immunol 36: 905–914.
40. Lorenzetti BB, Veiga FH, Canetti CA, Poole S, Cunha FQ, Ferreira SH (2002). Cytokine‐induced neutrophil chemoattractant 1 (CINC‐1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats. Eur Cytokine Netw 13: 456–461.
41. March DR, Proctor LM, Stoermer MJ, Sbaglia R, Abbenante G, Reid RC et al. (2004). Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol 65: 868–879.
42. Marchand F, Perretti M, McMahon SB (2005). Role of the immune system in chronic pain. Nat Rev Neurosci 6: 521–532.
43. O'Barr S, Cooper NR (2000). The C5a complement activation peptide increases IL‐1beta and IL‐6 release from amyloid‐beta primed human monocytes: implications for Alzheimer's disease. J Neuroimmunol 109: 87–94.
44. Safieh‐Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ (1995). Contribution of interleukin‐1 beta to the inflammation‐induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115: 1265–1275.
45. Sarma VJ, Huber‐Lang M, Ward PA (2006). Complement in lung disease. Autoimmunity 39: 387–394.
46. Schleimer RP (2004). Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc 1: 222–230.
47. Souza DG, Coutinho SF, Silveira MR, Cara DC, Teixeira MM (2000). Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats. Eur J Pharmacol 403: 121–128.
48. Torres M, Forman HJ (1999). Activation of several MAP kinases upon stimulation of rat alveolar macrophages: role of the NADPH oxidase. Arch Biochem Biophys 366: 231–239.
49. Twining CM, Sloane EM, Schoeniger DK, Milligan ED, Martin D, Marsh H et al. (2005). Activation of the spinal cord complement cascade might contribute to mechanical allodynia induced by three animal models of spinal sensitization. J Pain 6: 174–183.
50. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL (1998). Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti‐C5 therapy. Circulation 97: 2259–2267.
51. Vale ML, Benevides VM, Sachs D, Brito GA, da Rocha FA, Poole S et al. (2004). Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. Br J Pharmacol 143: 833–844.
52. van Beek J, Elward K, Gasque P (2003). Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 992: 56–71.
53. Verri Jr WA, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH (2006). Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development Pharmacol Ther 112: 116–138.
54. Ward PA (2004). The dark side of C5a in sepsis. Nat Rev Immunol 4: 133–142.
55. Weissmann G (2006). The pathogenesis of rheumatoid arthritis. Bull Hosp Jt Dis 64: 12–15.
56. Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, Gotze O (1992). Binding of fluorescein‐labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 79: 152–160.
57. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2003). A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 171: 5514–5520.
58. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM (2004). Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia–reperfusion in rats. J Surg Res 116: 81–90.
59. Woodruff TM, Crane JW, Proctor LM, Buller KM, Shek AB, de Vos K et al. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 20: 1407–1417.
60. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP et al. (2002). Antiarthritic activity of an orally active C5a receptor antagonist against antigen‐induced monarticular arthritis in the rat. Arthritis Rheum 46: 2476–2485.
61. Woolf CJ, Safieh‐Garabedian B, Ma QP, Crilly P, Winter J (1994). Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62: 327–331.